- Increasing research and development activities for producing Ebola vaccine is driving the market.
- Development of advanced and efficient vaccines can enable players in the target market to increase revenue share in the global market.
- The market in North America is expected to register the highest growth rate.
Ebola is a life threating disease, which is spread in humans from animals. Direct contact with infected person is one of major cause of spreading an infection. Symptoms of Ebola disease are high fever, sore throat, vomiting, diarrhea, headache, and muscular pain. There is no proper cure but symptomatic treatment such as treating infectious condition, maintaining electrolyte balance, and others aid in improving patient’s health.
The first five-year cumulative revenue (2019–2023) is projected to be more than $56.1 million which is expected to increase relatively over the latter part of the five-year forecast period. The global Ebola vaccine market is expected to value at over $5 million in 2019 and is expected to register a CAGR of 32.8%.
Global Ebola Vaccine Market: Market Dynamics
Major factor driving growth of the global Ebola vaccine market is increasing number of patient suffering from Ebola disease and growing demand for new medical devices and drugs among end users. For instance, according to data published World Health Organization (WHO) on 26th May 2019, total number of EVD cases in Democratic Republic of the Congo between April 2018 and 13 May 2019 was 1,920, including 1,826 confirmed and 94 probable cases. A total of 1,281 deaths were reported (overall case fatality ratio 67%), including 1,187 deaths among confirmed cases.
In addition, increasing research and development activities for producing Ebola vaccine, along with high government spending in developing and under-developed countries for development of healthcare infrastructure in order to facilitate advanced, effective, and cost-effective healthcare services are some major factors expected to drive growth of the global Ebola vaccine market.
Moreover, development of advanced and efficient vaccines can enable players in the target market to increase revenue share in the global market.
Global Ebola Vaccine Market: Market Forecast
The comprehensive research report comprises a complete forecast of the global Ebola vaccine market based on factors affecting the market and their impact in the foreseeable future. According to the forecast projections, revenue from the global Ebola vaccine market is expected to register a CAGR of 32.8% during the forecast period.
Global Ebola Vaccine Market: Segmental Snapshot
The market report has been segmented on the basis of virus strain and region. The virus strain segment includes chimpanzee adeno virus type 3-zaire ebola virus, recombinant vesicular stomatitis virus-zaire ebola virus, and adeno virus serotype 26- zaire ebola virus. The region includes the North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
By Virus Strain: The recombinant vesicular stomatitis virus-Zaire Ebola virus segment is expected to register highest CAGR of over 34.9% over the forecast period in the global market
By Region: The market in North America is expected to register highest CAGR of over 35.7% in the global Ebola vaccine market
Global Ebola Vaccine Market: Competitive Analysis
The research report on the global Ebola vaccine market includes profiles of some of the major companies such as Sarepta Therapeutics Inc., Mapp Biopharmaceutical Inc., Regeneron Pharmaceuticals, Inc., Merck & Company, Inc., GlaxoSmithKline plc., Novavax Inc., and GeoVax Labs Inc.
The Global Ebola Vaccine Market: Global Industry, Size, Share, Growth, Trends, and Forecast, 2019–2028 report has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the present scenario and the growth prospects of the global Ebola vaccine market for 2018–2028.